Guidance and quality standards awaiting development | Guidance

Showing 131 to 140 of 389

Guidance and quality standards awaiting development
Title	Type
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]	Technology appraisal guidance
Gambling	Quality standard
Gantenerumab for treating early Alzheimer's disease [TSID10668]	Technology appraisal guidance
Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]	Technology appraisal guidance
Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]	Technology appraisal guidance
Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies	HealthTech guidance
Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]	Technology appraisal guidance
Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]	Technology appraisal guidance
Giredestrant for adjuvant treatment of oestrogen-receptor positive HER2-negative early breast cancer [GID-TA12031	Technology appraisal guidance
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]	Technology appraisal guidance